Rational Design of HER2-Targeted Combination Therapies to Reverse Drug Resistance in Fibroblast-Protected HER2+ Breast Cancer Cells

Matthew D. Poskus,Jacob McDonald,Matthew Laird,Ruxuan Li,Kyle Norcoss,Ioannis K. Zervantonakis

DOI: https://doi.org/10.1007/s12195-024-00823-0

2024-10-13

Cellular and Molecular Bioengineering

Abstract:Fibroblasts, an abundant cell type in the breast tumor microenvironment, interact with cancer cells and orchestrate tumor progression and drug resistance. However, the mechanisms by which fibroblast-derived factors impact drug sensitivity remain poorly understood. Here, we develop rational combination therapies that are informed by proteomic profiling to overcome fibroblast-mediated therapeutic resistance in HER2+ breast cancer cells.

engineering, biomedical,biophysics,cell & tissue engineering,cell biology